Ionis Pharmaceuticals
IONS
338 hedge funds and large institutions have $4.96B invested in Ionis Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 104 reducing their positions, and 75 closing their positions.
37% more call options, than puts
Call options by funds: $48.6M | Put options by funds: $35.6M
11% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 104
0.59% more ownership
Funds ownership: 87.67% → 88.26% (+0.59%)
7% less funds holding
Funds holding: 365 → 338 (-27)
11% less capital invested
Capital invested by funds: $5.55B → $4.96B (-$593M)
32% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 75
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$147M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$39.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.3M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$37.1M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$36.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$79.1M |
| 2 |
BlackRock
New York
|
-$63.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$61.3M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$28.3M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$28.1M |
IONS Hedge Fund Activity: Q2 2021 in Review
338 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2021, worth a combined $4.96B — down 11% from $5.55B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of IONS and 51 opened new positions — a net loss of 24 holders — while 104 trimmed existing stakes and 115 added.
The largest buyer was ARK Investment Management, adding an estimated $147M. The largest seller was Invesco, cutting an estimated $79.1M.
- 338 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2021, down from 365 in Q1 2021.
- Funds reported $4.96B of Ionis Pharmaceuticals stock for Q2 2021, down 11% quarter-over-quarter.
- 51 funds opened new Ionis Pharmaceuticals positions in Q2 2021 and 75 closed out, a net change of -24 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2021 was ARK Investment Management, an estimated $147M added.
- The largest Ionis Pharmaceuticals seller in Q2 2021 was Invesco, an estimated $79.1M sold.
Based on aggregated 13F filings for Q2 2021.